Personalis EBITDA Margin 2018-2024 | PSNL
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Personalis (PSNL) over the last 10 years. The current EBITDA margin for Personalis as of December 31, 2024 is .
| Personalis EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-12-31 |
$0.09B |
$-0.06B |
-69.77% |
| 2024-09-30 |
$0.09B |
$-0.07B |
-74.16% |
| 2024-06-30 |
$0.08B |
$-0.08B |
-102.47% |
| 2024-03-31 |
$0.08B |
$-0.09B |
-121.33% |
| 2023-12-31 |
$0.07B |
$-0.10B |
-136.49% |
| 2023-09-30 |
$0.07B |
$-0.11B |
-152.11% |
| 2023-06-30 |
$0.07B |
$-0.10B |
-152.94% |
| 2023-03-31 |
$0.07B |
$-0.11B |
-155.07% |
| 2022-12-31 |
$0.07B |
$-0.11B |
-163.08% |
| 2022-09-30 |
$0.07B |
$-0.10B |
-137.68% |
| 2022-06-30 |
$0.08B |
$-0.09B |
-113.16% |
| 2022-03-31 |
$0.08B |
$-0.07B |
-91.25% |
| 2021-12-31 |
$0.09B |
$-0.06B |
-66.28% |
| 2021-09-30 |
$0.09B |
$-0.05B |
-60.00% |
| 2021-06-30 |
$0.08B |
$-0.04B |
-51.81% |
| 2021-03-31 |
$0.08B |
$-0.04B |
-47.50% |
| 2020-12-31 |
$0.08B |
$-0.04B |
-46.15% |
| 2020-09-30 |
$0.08B |
$-0.03B |
-39.47% |
| 2020-06-30 |
$0.07B |
$-0.03B |
-36.99% |
| 2020-03-31 |
$0.07B |
$-0.02B |
-31.43% |
| 2019-12-31 |
$0.07B |
$-0.02B |
-27.69% |
| 2019-06-30 |
$0.04B |
$-0.01B |
-19.05% |
| 2019-03-31 |
$0.04B |
$-0.01B |
-25.71% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.282B |
$0.085B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
